- Atlas
- Medicine & Health
- Immunotherapy
Immunotherapy
Immunotherapy is the practice of treating disease by manipulating the immune system itself—harnessing, redirecting, or restraining the body's own defenses rather than attacking a pathogen or tumor directly.
9 frameworks, from 1796 to today · Immunology · Medicine & Health
- Vaccination 1796-Present
- Antiserum 1890-1940
- Allergen immunotherapy 1911-Present
- Transplant immunosuppression 1954-Present
- Monoclonal antibody therapy 1975-Present
- Adoptive cell transfer 1980-Present
- Therapeutic cancer vaccination 1980-Present
- Checkpoint inhibitor 1996-Present
- CAR T-cell therapy 2011-Present
Overview
Immunotherapy is the practice of treating disease by manipulating the immune system itself—harnessing, redirecting, or restraining the body's own defenses rather than attacking a pathogen or tumor directly1. Its central idea is that the immune system is not merely a passive shield but a tool that can be deliberately tuned: switched on where it is failing, switched off where it is overreacting, or taught to recognize a target it has missed. What is at stake is enormous, because the immune system is implicated in nearly every disease—infections, cancers, allergies, autoimmune conditions, and the rejection of transplanted organs—and because the same system that can cure can also kill. The history of immunotherapy is the story of practitioners learning, often painfully, how to steer a system whose rules they only gradually came to understand.
Variolation and the Birth of Deliberate Immune Manipulation
The oldest form of immunotherapy is vaccination, and its roots reach back before anyone knew what an immune system was. In China and India, practitioners variolated against smallpox by introducing material from a mild case—scabs or pustule fluid—into a healthy person, hoping to induce a survivable infection that would confer lifelong protection. The practice spread to the Ottoman Empire and was observed there by Lady Mary Wortley Montagu, who brought it to Britain in the 1720s23. It worked often enough to be adopted, but it carried real risk: variolated patients could die or seed outbreaks.
The decisive turn came with Edward Jenner, a Gloucestershire physician who in 1796 inoculated a boy with cowpox matter and then exposed him to smallpox, finding him protected425. Jenner published his findings in 179842. The insight was that a related but harmless animal virus could confer immunity to the deadly human one—the principle of using a "vaccine" (from vacca, cow) to train the body without risking the disease425. Vaccination spread worldwide through the nineteenth century, and with Louis Pasteur's work on attenuated pathogens in the 1870s and 1880s—chicken cholera, anthrax, rabies—it became a general method: weaken a microbe, introduce it, and the body learns to resist the real thing. What practitioners could not yet explain was how it worked. That explanation would have to wait for the science of immunology.
Serum Therapy and the Humoral Turn
By the 1880s the germ theory had given medicine its targets, and the question became how the body fights them. Emil von Behring and Shibasaburo Kitasato showed in 1890 that the blood of animals immunized against diphtheria or tetanus contained a substance—an "antitoxin"—that could neutralize the toxin and, crucially, could be transferred to another animal to protect it678910. This was serum therapy: take blood serum from an immunized animal, give it to a sick patient, and the patient gains passive protection6. Behring won the first Nobel Prize in Physiology or Medicine in 1901 for diphtheria antitoxin, which saved many children's lives.
Serum therapy established that immunity could reside in the blood fluid—the "humoral" theory—and it created a practical industry of horses and other animals kept for antiserum production6. But it also revealed limits: sera were foreign proteins, and patients often reacted against them with "serum sickness," a fever-and-rash illness that was itself an immune reaction7. And a rival view, championed by Elie Metchnikoff, held that immunity was chiefly cellular—that phagocytes, cells that engulf microbes, were the real defenders1112. The humoral-versus-cellular debate would run for decades. Serum therapy also pointed toward a future idea: if antibodies could be given, perhaps they could be made specific and pure.
Allergen Immunotherapy and the Idea of Tolerance
A different strand emerged from the clinic. In the early twentieth century, physicians treating hay fever noticed that some patients improved after repeated exposure to the offending pollen1. In 1911 Leonard Noon and John Freeman in London reported that injecting increasing doses of grass pollen extract could desensitize patients—reduce their symptoms13. This was allergen immunotherapy, and its logic was the opposite of vaccination's: instead of provoking immunity to a microbe, it aimed to quiet an immune response that had gone wrong113. The mechanism was obscure, but the practice endured, and it introduced a durable principle—that the immune system can be taught tolerance, not only attack. The same principle would later underlie attempts to prevent transplant rejection and to treat autoimmune disease.
Transplantation and the Problem of Suppression
The mid-twentieth century brought a new problem: if the immune system attacks foreign tissue, how can a surgeon replace a failing organ? Early transplant attempts failed because the recipient's immune system destroyed the graft. The breakthrough came from understanding why: Peter Medawar and colleagues in Britain, studying skin grafts in rabbits and mice during the 1940s, showed that rejection was an active immune response, and that animals exposed to foreign tissue in early life could later accept it—a state called tolerance. Medawar shared the 1960 Nobel Prize with Macfarlane Burnet for this work14.
Clinically, the answer was to suppress the immune system. Total-body irradiation was tried, then drugs. The decisive drug was azathioprine, developed in the late 1950s and combined with steroids by Joseph Murray's team in Boston; in 1954 Murray had performed the first successful kidney transplant between identical twins (no rejection problem), and in the early 1960s immunosuppressed transplants between unrelated people began to succeed. Cyclosporine, introduced in the late 1970s, was a further leap: it suppressed rejection more selectively by blocking T-cell activation. Transplantation immunosuppression taught medicine that the immune system could be pharmacologically restrained—a lesson that cut both ways, since suppressed patients fell prey to infections and cancers. The dream of inducing specific tolerance, rather than blanket suppression, remained open.
The Antibody Revolution
The humoral tradition returned in a new form. In 1975 Georges Köhler and César Milstein developed hybridoma technology: they fused an antibody-producing B cell with an immortal myeloma cell, creating a hybrid cell line that could produce a single, uniform antibody indefinitely. These monoclonal antibodies—identical molecules aimed at one target—transformed both research and therapy. Early therapeutic monoclonals were mouse proteins and provoked human immune responses, but "humanization" and later fully human antibodies reduced this. By the 1990s and 2000s, monoclonal antibodies entered the clinic for cancer (rituximab against lymphoma, trastuzumab against HER2-positive breast cancer), autoimmune disease, and transplant rejection. The antibody, once a mysterious serum component, had become a designer drug.
Adoptive Cell Therapy and the Cancer Vaccination Dream
A parallel tradition sought to use cells themselves as therapy. Adoptive cell therapy means taking immune cells out of the body, expanding or engineering them, and returning them to fight disease. Early work in the 1980s by Steven Rosenberg and others used tumor-infiltrating lymphocytes—immune cells found inside tumors—expanded in the laboratory and reinfused into patients, with occasional dramatic responses in melanoma115. The approach was laborious and worked only in some cancers, but it proved that a patient's own cells could be turned into a treatment.
Alongside it ran therapeutic cancer vaccination: the hope that a vaccine could teach the immune system to attack a tumor, much as it attacks a microbe. Despite decades of effort and many trials, cancer vaccines largely disappointed, because tumors are poor immunogens and actively suppress immune responses. The failures were instructive: they showed that the obstacle was not merely recognition but the tumor's ability to shut down the attack.
Checkpoint Blockade: Releasing the Brakes
That obstacle was named and then dismantled. The immune system has built-in brakes—"checkpoints"—that prevent it from attacking normal tissue. Tumors exploit these brakes. In the 1990s James Allison showed that blocking CTLA-4, a brake on T cells, could unleash anti-tumor immunity in mice; in 1996 his group reported that anti-CTLA-4 antibodies caused tumor rejection. Independently, Tasuku Honjo's work on PD-1, another inhibitory receptor, laid the groundwork for a second brake. The first checkpoint-blockade drug, ipilimumab (anti-CTLA-4), was approved in 2011 for melanoma, and PD-1 blockers followed. Allison and Honjo shared the 2018 Nobel Prize1151617. Checkpoint blockade was a conceptual revolution: instead of adding an attack, it removed a restraint, and in some patients—a minority, but sometimes for years—it produced durable remissions in cancers that had been uniformly fatal. It also produced a new class of side effects, autoimmune-like toxicities, because releasing the brakes can turn the immune system on the body itself.
CAR T Cells: Engineering the Attack
The most recent major turn combines cell therapy with genetic engineering. Chimeric antigen receptor (CAR) T-cell therapy takes a patient's T cells, engineers them to carry a synthetic receptor that recognizes a specific marker on tumor cells, and reinfuses them115. The receptor—a "chimeric antigen receptor"—joins an antibody-like recognition domain to T-cell signaling machinery, so the engineered cell both finds and kills its target. Early clinical success came in the 2010s against B-cell leukemias and lymphomas, where the target (CD19) is present on malignant and normal B cells alike; the treatment can be curative but also destroys normal B cells and can trigger severe "cytokine release syndrome," a dangerous inflammatory storm. CAR T-cell therapy was approved in 2017 for certain leukemias and lymphomas, and it opened the question of how to extend the approach to solid tumors, which lack such clean targets.
The Present: A Toolkit of Approaches
Immunotherapy today is not one method but a family of them, each descending from a distinct strand of this history. Vaccination remains the most widely used immunotherapy in the world, now with mRNA platforms that can be redesigned rapidly. Allergen immunotherapy persists as desensitization for allergy113. Transplantation relies on refined immunosuppressive drugs and increasingly on antibody-based induction. Monoclonal antibodies are a mainstay of cancer and autoimmune therapy. Checkpoint blockade and CAR T cells are the newest and most dramatic, and they have made cancer immunotherapy a central clinical field. Adoptive cell therapy continues to expand beyond CAR T cells, and therapeutic cancer vaccination has been revived by better understanding of tumor immunology.
The open questions are the ones the history keeps posing. How can the immune system be turned on against cancer without turning on the body? How can tolerance be induced specifically, so that transplants survive and autoimmune disease is quieted without blanket suppression? Why do checkpoint blockade and CAR T cells work spectacularly in some patients and not at all in others? And how can the power of the immune system be extended to the solid tumors that still resist it? The field's history is a record of learning to steer a system that was never designed to be steered—and of discovering, again and again, that its brakes and accelerators are more intricate than they first appeared.
References
- Immunotherapy (introduction, Allergen immunotherapy, Adoptive cell therapy, Cancer), Wikipedia
- Vaccine (introduction, History), Wikipedia
- Immunization (History), Wikipedia
- Vaccination (introduction, History), Wikipedia
- Smallpox vaccine, Wikipedia
- Antiserum (History, introduction), Wikipedia
- Antitoxin (History of antitoxin, introduction), Wikipedia
- Antibody (History), Wikipedia
- Passive immunity (History and applications of artificial passive immunity), Wikipedia
- Antivenom (History), Wikipedia
- Immunology, Wikipedia
- Immune system (History of immunology), Wikipedia
- Allergen immunotherapy (introduction, History), Wikipedia
- Immune tolerance (Historical background), Wikipedia
- Cancer immunotherapy (History, introduction), Wikipedia
- Checkpoint inhibitor, Wikipedia
- Immune checkpoint, Wikipedia
The frameworks of Immunotherapy
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1796-Present
Vaccination
How can exposure to a mild form of a disease prevent the severe form?
- 1890-1940
Antiserum
Can protective substances from immune blood be transferred to cure disease?
- 1911-Present
Allergen immunotherapy
Can repeated exposure to an allergen reduce allergic symptoms?
- 1954-Present
Transplant immunosuppression
How can a transplanted organ be kept from being rejected?
- 1975-Present
Monoclonal antibody therapy
Can a single pure antibody be made to target one molecule?
- 1980-Present
Adoptive cell transfer
Can a patient's own immune cells be used as a treatment?
- 1980-Present
Therapeutic cancer vaccination
Can a vaccine teach the immune system to attack a tumor?
- 1996-Present
Checkpoint inhibitor
Can removing the immune system's brakes unleash an attack on cancer?
- 2011-Present
CAR T-cell therapy
Can engineered immune cells be made to hunt and kill cancer?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Monoclonal antibody therapy grew out of Antiserum
Serum therapy showed that antibodies in blood could be given as therapy, but sera were impure mixtures of foreign proteins. Köhler and Milstein's hybridoma method produced single, uniform antibodies, realizing the long-sought goal of specific and pure antibody therapy.
Carried by Georges Köhler; César Milstein.
CAR T-cell therapy grew out of Adoptive cell transfer
CAR T-cell therapy is a branch of adoptive cell transfer: T cells are removed, genetically engineered to express a chimeric antigen receptor, expanded, and reinfused. It grew directly out of the Rosenberg-era practice of expanding and returning a patient's own immune cells.
Carried by Steven Rosenberg.
Antiserum influenced by Vaccination
Vaccination established that immunity could be deliberately induced and transferred between individuals. Behring and Kitasato's antitoxin work built on the immunized-animal model of vaccine production, using immunized animals as a source of protective serum rather than as vaccine recipients.
Carried by Emil von Behring; Shibasaburo Kitasato.
Allergen immunotherapy influenced by Vaccination
Allergen immunotherapy adopted vaccination's method of repeated injection of an extract to alter the immune response, but inverted its aim: instead of provoking immunity to a microbe, it sought to quiet an allergic response. Noon and Freeman's 1911 pollen-injection reports carried this over.
Carried by Leonard Noon; John Freeman.
Monoclonal antibody therapy influenced by Transplant immunosuppression
Transplant immunosuppression created a clinical need for more selective agents than drugs like cyclosporine. Monoclonal antibodies against T-cell targets were developed partly to prevent graft rejection with greater specificity, and anti-CD3 antibodies entered transplant practice in the 1980s.
Therapeutic cancer vaccination rival of Adoptive cell transfer
Adoptive cell transfer and therapeutic cancer vaccination were contemporaneous strategies for turning the immune system against tumors, one by supplying expanded cells and the other by immunizing to provoke them. They competed for the same clinical goal and patient populations through the 1980s and 1990s.
Beyond the field
Where Immunotherapy's ideas came from in other fields, and what they led to there: the strongest 12 of 60 links.
Vaccination grew out of Variolation in Vaccinology
Jenner's 1796 cowpox vaccination built directly on the practice of variolation, using the same inoculation logic but substituting cowpox material; variolation's demonstrated protection against smallpox was the model vaccination refined.
Carried by Edward Jenner.
Vaccination led to Immunologic adjuvant in Vaccinology
Adjuvants arose directly from vaccination practice, as a means of strengthening the response to vaccines. The technique is a refinement within the older practice.
Carried by Gaston Ramon.
Allergen immunotherapy influenced by Allergy and Contact Dermatitis in Dermatology
Noon and Freeman's 1911 pollen immunotherapy grew out of the newly defined category of allergy and hay fever; the clinical allergy framework supplied the disease concept the therapy treated.
Carried by John Freeman; Leonard Noon.
Transplant immunosuppression influenced by Immune tolerance in Fundamental Immunology
Medawar's demonstration of acquired immune tolerance in 1953 gave transplant immunosuppression its theoretical basis, showing that the immune system could be made to accept foreign tissue.
Carried by Peter Medawar.
Monoclonal antibody therapy influenced Checkpoint inhibitor in Tumor Immunology
Checkpoint inhibitors are monoclonal antibodies, and the technology of hybridoma-derived and later humanized antibodies supplied the therapeutic agents. Without monoclonal antibody production and engineering, anti-CTLA-4 and anti-PD-1 drugs could not exist.
Carried by Georges Köhler; César Milstein.
Monoclonal antibody therapy influenced Cancer Immunotherapy in Medical Oncology
Monoclonal antibody technology, from Kohler and Milstein's hybridoma method onward, produced the checkpoint-blocking antibodies (ipilimumab, approved 2011; PD-1 inhibitors) that define modern cancer immunotherapy. Without antibody engineering the field's central drugs would not exist.
Carried by Georges Köhler; César Milstein; Ipilimumab (2011).
Monoclonal antibody therapy influenced Targeted Therapy in Oncology
Monoclonal antibody therapy supplied the targeting technology: hybridoma-derived antibodies directed at a chosen antigen became the first targeted agents, and trastuzumab against HER2 showed a molecular target could be hit clinically. Targeted therapy built directly on this antibody platform.
Carried by Georges Köhler; César Milstein; Trastuzumab (1998).
Adoptive cell transfer influenced CAR T cell in Pediatric Hematology And Oncology
CAR T cells are a form of adoptive cell transfer: the earlier practice of harvesting and reinfusing immune cells supplied the clinical template, and the first CAR T cells were produced by transducing autologous T cells later reinfused into patients.
Carried by Steven Rosenberg.
Adoptive cell transfer led to CAR T cell in Tumor Immunology
CAR T cells are a branch of adoptive cell transfer: the same ex vivo expansion and reinfusion of patient T cells, with the added step of genetically installing a chimeric receptor. The first CAR constructs were made by groups working within the adoptive transfer tradition.
Carried by Zelig Eshhar; Steven Rosenberg.
Checkpoint inhibitor influenced by Monoclonal antibody therapy in Tumor Immunology
Checkpoint inhibitors are monoclonal antibodies; hybridoma technology and antibody humanization supplied the molecules (ipilimumab, nivolumab) that block CTLA-4 and PD-1. Without monoclonal antibody therapy the checkpoint drugs could not exist.
Carried by Georges Köhler; César Milstein.
Checkpoint inhibitor influenced by Immune checkpoint in Autoimmunity
The concept of the immune checkpoint, especially CTLA-4 and PD-1 as inhibitory receptors, was the direct basis for blocking those molecules therapeutically. The 1996 demonstration that CTLA-4 blockade unleashes antitumor immunity turned the checkpoint concept into a drug class.
Carried by James P. Allison.
CAR T-cell therapy grew out of Adoptive cell transfer in Tumor Immunology
CAR T-cell therapy is a branch of adoptive cell transfer: engineered T cells are expanded ex vivo and reinfused, inheriting the transfer methodology and the use of lymphodepletion and IL-2 from tumor-infiltrating lymphocyte therapy. The chimeric antigen receptor was grafted onto the adoptive transfer platform.
Carried by Steven Rosenberg; Zelig Eshhar.

Immunotherapy is a planet in Nousfarer
Its city has a tower for each of these 9 frameworks. Land, walk in, and climb one concept at a time.
Land on ImmunotherapyRelated fields
Fields its ideas are linked to
- Tumor Immunology 18 links
- Autoimmunity 5 links
- Vaccinology 5 links
- Fundamental Immunology 4 links
- Oncology 4 links
- Medical Oncology 3 links
- Pediatric Hematology And Oncology 3 links
- Endocrinology And Diabetes 2 links
- Hematology 2 links
- Infectious Diseases 2 links
- Hematologic Malignancies 2 links
- Transplant Surgery 2 links